COMBINED VACCINES IN PEDIATRIC PRACTICE: WHEN THE PERTUSSIS VACCINE IS FUN!
https://doi.org/10.15690/pf.v9i4.386
Abstract
Today the tendency towards reducing the invasive techniques in pediatric patients is of current importance. This also applies to vaccination. Creating a modern multi-vaccine reduces the number of painful injections to infants, because most of the vaccines are introduced in the first year of the life. The article presents the convincing data concerning the combined vaccines efficiency and safety. There is shown the possibility of their effective combination with other monovaccines, the absence of adverse reactions summation and even their reduction by reducing the multiplicity of the vaccine introduced (in the case of monovaccines).
About the Author
V. K. Tatochenko
Scientific Center of Children’s Health, RAMS, Moscow
Russian Federation
Russian Federation
References
1. Cherry J. et al. A search for serologic correlates of immunity to Bordetella pertussiscoughs illnesses. Vaccine. 1998; 16: 1901–1906.
2. Dhillon S. DTPa-HBV-IPV/Hib vaccine (Infanrix hexa). A review of its use as primary and booster vaccination. Drugs. 2010; 70 (8): 1022–1058.
3. Zepp F., Schmitt H-J., Cleerboat J. et al. Rewiev of 8 years of experience with Infanrix hexa (DTPa — HBV-IPV/Hib hexavalent vaccine). Expert rew. Vaccine. 2009; 8 (6): 663–676.
4. Zinke M., Kappes R., Kindler K. et al. Immune memory to hepatitis B virus in 4–9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Human Vaccines. 2009; 5 (9): 592–599.
5. Pichichero M. E., Blatter M. M., Reisinger K. S. et al. Impact o f a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussishepatitis B-inactivated poliovirus — Haemophilus influenzae type b combination vaccination. Pediatr Infect Dis J. 2002; 21 (9): 854–859.
6. Fong-Seng L., Htay-Htay H., Jacquet J.-M., Bock H. L. Primary vac cination of infants against hepatitis b can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis — Haemophilus influenzae type B vaccine. Annals Academy of Medicine. 2007; 36 (10): 801–806.
7. Omenaca F., Garcia-Sicilia J., Garcia-Corbeira P. et al. Response of preterm newborns to immunization with a hexavalent diphtheriatetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemo philus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics. 2005; 116 (6): 1292–1298.
8. Kalies H., Grote V., Siedler A. et al. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany’s experience after 5 years of licensure. Vaccine. 2008; 26 (20): 2545–2552.
9. Schmitt H. J., von Koеnig C. H., Neiss A. et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 1996; 275 (1): 37–41.
10. Greco D., Salmaso S., Mastrantonio P. et al. On behalf of the Progetto Pertosse Working Group A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med. 1996; 334 (6): 341–348.
11. Информационное Письмо Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека от 18 мая 2007 г. № 0100/5137-07-32 Приложение № 2 «О тактике иммунизации при удлинении интервалов между прививками против гепатита В». 12. Gimenez-Sanchez F., Kieninger D. M., Kueper K. et al. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. Vaccine. 2011; 29: 6042– 6048.
12. Vanden Bergh M. R., Spijkerman J., Francois N. et al. Immunogenicity, safety, and reactogenicity of the 10-valen tpneumococca lnontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccinations chedule in the Netherlands. A randomized controlled trial. Pediatr Infect Dis J. 2011; 30: 170–178.
13. Tejedor J., Omenaca F., Garcia-Sicilia J. et al. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J. 2004; 23 (12): 1109–1115.
14. Knuf M., Pantazi-Chatzikonstantinou A., Pfletschinger U. et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanustoxoidconjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children. Vaccine. 2011; 29: 4264–4273.
15. Tejedor J. C., Garcia-Sicilia J., Grunert D. et al. Co-administration of the new 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHID-CV) with other routine paediatric vaccines. 6th International Symposium on Pneumococci & Pneumococcal Diseases (ISPPD-6). Reykjavik, Iceland. 8–12 June 2008.
16. ВОЗ, ЮНИСЕФ, Всемирный Банк. Положение в мире относительно вакцин и иммунизации. 3-е издание. ВОЗ, Женева. 2009.
17. Hviid A., Wohlfahrt J., Stellfeld V., Melbyt M. Childhood vaccination and nontargeted infectious disease hospitalization. JAMA. 2005; 294 (6): 699–705.
Review
For citations:
Tatochenko V.K. COMBINED VACCINES IN PEDIATRIC PRACTICE: WHEN THE PERTUSSIS VACCINE IS FUN! Pediatric pharmacology. 2012;9(4):26-31. (In Russ.) https://doi.org/10.15690/pf.v9i4.386
Views:
1433
Email this article 